Skip to main content

Safety and Tolerability of Lamotrigine for Bipolar Disorder

Drug Safety volume 27, pages 173–184 (2004)Cite this article

Abstract

Tolerability and safety are important considerations in optimising pharmacotherapy for bipolar disorder. This paper reviews the tolerability and safety of lamotrigine, an anticonvulsant recommended in the 2002 American Psychiatric Association guidelines as a first-line treatment for acute depression in bipolar disorder and one of several options for maintenance therapy.

This paper reviews the tolerability and safety of lamotrigine using data available from a large programme of eight placebo-controlled clinical trials of lamotrigine enrolling a total of nearly 1800 patients with bipolar disorder. This review is the first to collate all the safety information from these clinical trials, including data from four unpublished studies.

The results these trials in which 827 patients with bipolar disorder were given lamotrigine as monotherapy or adjunctive therapy for up to 18 months for a total of 280 patient-years of exposure demonstrated that lamotrigine is well-tolerated with an adverse-event profile generally comparable with that of placebo. The most common adverse event with lamotrigine was headache. Lamotrigine did not appear to destabilise mood and was not associated with sexual adverse effects, weight gain, or withdrawal symptoms.

Few patients experienced serious adverse events with lamotrigine, and the incidence of withdrawals because of adverse events was low. Serious rash occurred rarely (0.1% incidence) in the clinical development programme including both controlled and uncontrolled clinical trials. These findings — considered in the context of data showing lamotrigine to be effective for bipolar depression — establish lamotrigine as a well-tolerated addition to the psychotropic armamentarium.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 49.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Table I
Table II
Table III
Table IV
Table V
Table VI
Table VII
Table VIII

References

  1. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79–88

    Article  PubMed  CAS  Google Scholar 

  2. Kusumakar V, Yatham LN. Lamotrigine treatment of rapid cycling bipolar disorder. Am J Psychiatry 1997; 154: 1171–2

    PubMed  CAS  Google Scholar 

  3. Sporn J, Sachs GS. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 1997; 17: 185–9

    Article  PubMed  CAS  Google Scholar 

  4. Walden J, Hesslinger B, van Calker D, et al. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry 1996; 29: 193–5

    Article  PubMed  CAS  Google Scholar 

  5. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000; 61: 841–50

    Article  PubMed  CAS  Google Scholar 

  6. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharm 2000; 20: 607–14

    Article  CAS  Google Scholar 

  7. Bowden CL, Calabrese JR, McElroy SL, et al. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol Psychiatry 1999; 45: 953–8

    Article  PubMed  CAS  Google Scholar 

  8. Calabrese JR, Bowden CL, McElroy SL, et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999; 156: 1019–23

    PubMed  CAS  Google Scholar 

  9. Berk M. Lamotrigine and the treatment of mania in bipolar disorder. Eur Neuropsychopharmacol 1999; 9Suppl. 4: S119–23

    Article  PubMed  CAS  Google Scholar 

  10. Ichim L, Berk M, Brook S. Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatry 2000; 12: 5–10

    PubMed  CAS  Google Scholar 

  11. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392–400

    Article  PubMed  CAS  Google Scholar 

  12. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013–24

    Article  PubMed  CAS  Google Scholar 

  13. Howland RH. Induction of mania with serotonin reuptake inhibitors. J Clin Psychopharmacol 1996; 16: 425–7

    Article  PubMed  CAS  Google Scholar 

  14. Himmelhoch JM, Thase MD, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148: 910–6

    PubMed  CAS  Google Scholar 

  15. Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 1987; 144(11): 1403–11

    PubMed  CAS  Google Scholar 

  16. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994; 55: 391–3

    PubMed  CAS  Google Scholar 

  17. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001; 15(8): 906–12

    Google Scholar 

  18. American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder. Am J Psychiatry 2002; 159: 1–50

    Google Scholar 

  19. Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Am J Psychiatry 2002; 159: 1927–9

    Article  PubMed  Google Scholar 

  20. Jamison KR, Gerner RH, Goodwin FK. Patient and physician attitudes toward lithium: relationship to compliance. Arch Gen Psychiatry 1979; 36: 866–9

    Article  PubMed  CAS  Google Scholar 

  21. Brodie MJ, Richens A, Yuen AWC, et al. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 345: 476–9

    Article  PubMed  CAS  Google Scholar 

  22. Steiner TJ, Dellaportas CI, Findley LJ. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999; 40: 601–7

    Article  PubMed  CAS  Google Scholar 

  23. Messenheimer JA, Mullens EL, Giorgi L, et al. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998; 18(4): 281–96

    Article  PubMed  CAS  Google Scholar 

  24. Uvebrant P, Bauzien PR. Intractable epilepsy in children: the efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics 1994; 25: 284–9

    Article  PubMed  CAS  Google Scholar 

  25. Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001; 56: 172–7

    Article  PubMed  CAS  Google Scholar 

  26. Lamictal® (lamotrigine) product information. Research Triangle Park (NC): Glaxo Wellcome Inc, 2001 May

  27. Matsuo F. Lamotrigine. Epilepsia 1999; 40Suppl. 5: S30–6

    Article  PubMed  CAS  Google Scholar 

  28. GlaxoSmithKline Study SCAB2005, 2001. (Data on file)

  29. GlaxoSmithKline Study SCAA2010, 1999. (Data on file)

  30. GlaxoSmithKline Study SCAA2008, 2000. (Data on file)

  31. GlaxoSmithKline Study SCAB2009, 1999. (Data on file)

  32. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

  33. Kupfer DJ, Frenk E, Grochocinski VJ, et al. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002; 63: 120–5

    Article  PubMed  Google Scholar 

  34. GlaxoSmithKline 2002. (Data on file)

  35. Jamison KR. Suicide and bipolar disorder. J Clin Psychiatry 2000; 61Suppl. 9: 47–51

    PubMed  Google Scholar 

  36. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials. Arch Gen Psychiatry 2000; 57: 311–7

    Article  PubMed  CAS  Google Scholar 

  37. Calabrese JR, Rapport DJ, Kimmel SE, et al. Controlled trials in bipolar I depression: focus on switch rates and efficacy. Eur Neuropsychopharmacol 1999; 9Suppl. 4: S109–12

    Article  PubMed  CAS  Google Scholar 

  38. Compton MT, Nemeroff CB. The treatment of bipolar depression. J Clin Psychiatry 2000; 61Suppl. 9: 57–67

    PubMed  CAS  Google Scholar 

  39. Peet M. Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164: 549–50

    Article  PubMed  CAS  Google Scholar 

  40. Guberman AH, Besag FMC, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999; 40: 985–91

    Article  PubMed  CAS  Google Scholar 

  41. Gitlin MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J Clin Psychiatry 1994; 55: 406–13

    PubMed  CAS  Google Scholar 

  42. Ferguson JM. The effects of antidepressants on sexual functioning in depressed patients: a review. J Clin Psychiatry 2001; 62Suppl. 3: 22–34

    PubMed  CAS  Google Scholar 

  43. McIntyre RS. Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. J Clin Psychiatry 2002; 63Suppl. 3: 15–20

    PubMed  CAS  Google Scholar 

  44. Vieta E, Reinares M, Corbella B, et al. Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharmacol 2001; 21: 469–73

    Article  PubMed  CAS  Google Scholar 

  45. Roy Chengappa KN, Levine J, Rathore D, et al. Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur Psychiatry 2001; 16: 186–90

    Article  PubMed  CAS  Google Scholar 

  46. Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf 2001; 24(13): 969–78

    Article  PubMed  CAS  Google Scholar 

  47. Devinsky O, Vuong A, Hammer A, et al. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology 2000; 54: 973–5

    Article  PubMed  CAS  Google Scholar 

  48. Sachs GS, Guille C. Weight gain associated with use of psychotropic medications. J Clin Psychiatry 1999; 60(S21): 16–9

    PubMed  Google Scholar 

  49. Odishaw J, Chen C. Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects. Pharmacotherapy 2000; 20: 1448–53

    Article  PubMed  CAS  Google Scholar 

  50. Chen C, Veronese L, Yin Y. The effects of lamotrigine on the pharmacokinetics of lithium. Br J Clin Pharmacol 2000; 50: 193–5

    Article  PubMed  CAS  Google Scholar 

  51. Besag FM, Berry DJ, Pool F, et al. Carbamazepine toxicity with lamotrigine: pharmacokinetic of pharmacodynamic interaction? Epilepsia 1998; 39: 183–7

    Article  PubMed  CAS  Google Scholar 

  52. Kanner AM, Frey M. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology 2000; 55: 588–91

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Dr Charles Bowden was a primary investigator in the clinical development programme for lamotrigine for bipolar disorder and has served as a consultant for GlaxoSmithKline. Dr Gregory Asnis and Dr Lawrence Ginsberg served as contributing investigators in the clinical development programme for lamotrigine for bipolar disorder. Dr Beth Bentley, Dr Robert Leadbetter and Dr Robin White are full-time employees of GlaxoSmithKline. The development of this manuscript was funded by an unrestricted grant from GlaxoSmithKline.

The authors thank Jane Saiers, PhD, for assistance with writing this manuscript.

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas, 78229-3900, USA

    Charles L. Bowden

  2. Department of Psychiatry, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, New York, USA

    Gregory M. Asnis

  3. Red Oak Psychiatric Associates, Houston, Texas, USA

    Lawrence D. Ginsberg

  4. GlaxoSmithKline, Research Triangle Park, North Carolina, USA

    Beth Bentley, Robert Leadbetter & Robin White

Authors
  1. Charles L. Bowden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory M. Asnis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lawrence D. Ginsberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Beth Bentley
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert Leadbetter
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Robin White
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles L. Bowden.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bowden, C.L., Asnis, G.M., Ginsberg, L.D. et al. Safety and Tolerability of Lamotrigine for Bipolar Disorder. Drug-Safety 27, 173–184 (2004). https://doi.org/10.2165/00002018-200427030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200427030-00002

Keywords

  • Bipolar Disorder
  • Valproate
  • Lamotrigine
  • Toxic Epidermal Necrolysis
  • Suicide Event